Lakefront Biotherapeutics NV
LKFT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001421876
No open-market purchases or sales by Lakefront Biotherapeutics NV insiders were filed in the last 90 days; 76 institutions reported holding it in 13F filings for Q2 2026, worth $960.3M in total; Greenlight Capital is the only superinvestor holding it.
Other share classesGLPGF
Q2 2023 vs. Q1 2023
How the institutions holding Lakefront Biotherapeutics NV changed between Q1 2023 and Q2 2023.
All holders in Q2 2023All holders in Q1 2023
| Measure | Q1 2023 | Q2 2023 | Change |
|---|---|---|---|
| Holders | 76 | 76 | 0 |
| Shares | 18.2M | 19.7M | +1.49M (+8.2%) |
| Value | $703.8M | $801.4M | +$97.5M (+13.9%) |
New holders (8)
Institutions that held Lakefront Biotherapeutics NV at the end of Q2 2023 but not at the end of Q1 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Pictet Asset Management SA | 167,274 | $6.80M | 0.01% |
| D. E. Shaw & Co., Inc. | 16,547 | $672.8K | 0.00% |
| Engineers Gate Manager LP | 5,574 | $226.6K | 0.01% |
| Commonwealth Equity Services, LLC | 5,500 | $224.0K | 0.00% |
| Rhumbline Advisers | 2,981 | $121.2K | 0.00% |
| Wells Fargo & Company | 202 | $8.21K | 0.00% |
| Aquatic Capital Management LLC | 200 | $8.00K | 0.00% |
| Parallel Advisors, LLC | 9 | $366 | 0.00% |
Sold out (8)
Institutions that held Lakefront Biotherapeutics NV at the end of Q1 2023 and filed for Q2 2023 without it.
| Institution | Shares, Q1 2023 | Value, Q1 2023 |
|---|---|---|
| Caption Management, LLC | 19,826 | $766.1K |
| Squarepoint Ops LLC | 18,251 | $705.2K |
| Aigen Investment Management, LP | 11,037 | $426.5K |
| XTX Topco Ltd | 8,416 | $325.2K |
| Axq Capital, LP | 5,389 | $208.2K |
| Optiver Holding B.V. | 2,246 | $86.8K |
| Belpointe Asset Management LLC | 6 | $213 |
| Values First Advisors, Inc. | 0 | $1 |